GlassScriptPhysician profile
Alec D Weisberg
NPI 1710935952
$4,254.82
in general payments reported to CMS, 2019-2025
32 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $304 · 2021: $1,199 · 2022: $703 · 2023: $389 · 2024: $729 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $603.16 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $457.17 | 2019-2025 | Watchman Flx, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $331.41 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $264.67 | 2019-2024 | Xarelto |
| Pfizer INC. | $254.96 | 2019-2025 | |
| Abiomed | $247.00 | 2021-2022 | |
| Medtronic, INC. | $245.61 | 2021-2024 | Hawkone |
| Novartis Pharmaceuticals Corporation | $227.25 | 2019-2025 | |
| Abbott Laboratories | $226.54 | 2019-2023 | Mitraclip |
| Sanofi-Aventis U.S. LLC | $177.11 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $171.50 | 2021-2025 | Verquvo |
| Lantheus Medical Imaging, INC. | $157.18 | 2022-2025 | Definity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.94 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $97.70 | 2021-2024 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $97.64 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.09 | 2022-2025 | Lifevest |
| Novo Nordisk INC | $80.82 | 2024-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $50.81 | 2020-2025 | Amvuttra |
| Philips North America LLC | $48.17 | 2022-2025 | Neoview |
| Esperion Therapeutics, INC. | $38.50 | 2021-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $38.49 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $32.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.32 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $23.77 | 2025 | |
| Shockwave Medical, INC | $23.74 | 2025 | |
| Cardiva Medical, INC. | $21.75 | 2024 | Cardiva Vascade 6/7f Vcs |
| Astrazeneca Pharmaceuticals LP | $21.74 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.96 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $20.33 | 2023 | Arcalyst |
| Penumbra, INC. | $18.94 | 2021 | |
| Lilly USA, LLC | $18.87 | 2025 | Zepbound |
| Amryt Pharma Holdings LTD | $17.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alec Weisberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.